The impact of serum digoxin concentration and enalapril therapy in patients with CHF: the SOLVD trial revisited

Richard Sheppard(Jewish General Hospital), Michel White(Montreal Heart Institute), Normand Racine(Montreal Heart Institute), Martial G. Bourassa(Montreal Heart Institute), Sylvie Lévesque, Anique Ducharme(Montreal Heart Institute), Jean‐Claude Tardif(Montreal Heart Institute), Simon deDenus(Montreal Heart Institute)
Journal of Cardiac Failure
August 1, 2004
10.1016/j.cardfail.2004.06.258
Cited by 1

Related Papers

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
|New England Journal of Medicine|2018|3.2k
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
|New England Journal of Medicine|2015|2.3k
Effect of Very High-Intensity Statin Therapy on Regression of Coronary Atherosclerosis
|JAMA|2006|2k
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
|New England Journal of Medicine|2012|2k
Rhythm Control versus Rate Control for Atrial Fibrillation and Heart Failure
|New England Journal of Medicine|2008|1.6k